An Open Label, Longitudinal Study of the Effects of Subcutaneous Acute and Chronic Pasireotide (SOM230) Therapy on Adrenocorticotrophic Hormone and Tumour Volume in Patients with Nelson's Syndrome.

Trial Profile

An Open Label, Longitudinal Study of the Effects of Subcutaneous Acute and Chronic Pasireotide (SOM230) Therapy on Adrenocorticotrophic Hormone and Tumour Volume in Patients with Nelson's Syndrome.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 08 Nov 2016

At a glance

  • Drugs Pasireotide (Primary)
  • Indications Nelson's syndrome
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 Nov 2014 According to the ClinicalTrials.gov record, status changed from active, no longer recruiting to discontinued.
    • 07 Oct 2014 Status changed from recruiting to active, no longer recruiting as reported by United Kingdom Clinical Research Network record.
    • 11 Dec 2013 Accrual to date is 47% according to United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top